title: Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer.
abstract: There is a need to improve the prognostic and predictive indicators in non-small cell lung cancer (NSCLC). At present, the main focus is on genetic predictive markers while the prognostic value of the standard blood variables related to haematopoiesis has been subjected to relatively limited attention. To study the prognostic potential of haemoglobin (Hgb), platelet (Plt) and white blood cell (WBC) levels at time of diagnosis in NSCLC patients, 835 NSCLC patients, stage I-IV, who received radiotherapy with curative intention (>50 Gy), were included in the study. WBC, Plt, Hgb, gender, age at diagnosis, stage, surgery and first-line chemotherapy were studied in relation to overall survival. For patients with Hgb < 110 g/L and Hgb ≥ 110 g/L), the median survival was 11.2 and 14.5 months, respectively (p = 0.0032). For WBC > 9.0 × 10(9)/L and < 9.0 × 10(9)/L, the median survival was 11.6 and 15.4 months, respectively (p < 0.0001). For Plt > 350 × 10(9)/L and <350 × 10(9)/L, the median survival was 11.2 and 14.9 months, respectively (p < 0.0001). The median survival in patients with pathological results in all three markers was half of that in patients with normal levels of all three markers (8.0 and 16.0 months, respectively (p < 0.0001). The level of the three studied haematological biomarkers corresponds significantly to outcome in NSCLC. These results indicate that standard haematological variables may be used as guidance for the clinician in the decision-making regarding treatment intensity and patient information.
authors.affiliation: Section of Oncology, Department of Radiology, Oncology and Radiation Sciences, Uppsala University, 751 85, Uppsala, Sweden.
authors.forename: Georg
authors.initials: G
authors.lastname: Holgersson
authors.forename: Martin
authors.initials: M
authors.lastname: Sandelin
authors.forename: Even
authors.initials: E
authors.lastname: Hoye
authors.forename: Stefan
authors.initials: S
authors.lastname: Bergström
authors.forename: Roger
authors.initials: R
authors.lastname: Henriksson
authors.forename: Simon
authors.initials: S
authors.lastname: Ekman
authors.forename: Jan
authors.initials: J
authors.lastname: Nyman
authors.forename: Martin
authors.initials: M
authors.lastname: Helsing
authors.forename: Signe
authors.initials: S
authors.lastname: Friesland
authors.forename: Margareta
authors.initials: M
authors.lastname: Holgersson
authors.forename: Kristina Lamberg
authors.initials: KL
authors.lastname: Lundström
authors.forename: Christer
authors.initials: C
authors.lastname: Janson
authors.forename: Elisabet
authors.initials: E
authors.lastname: Birath
authors.forename: Charlotte
authors.initials: C
authors.lastname: Mörth
authors.forename: Thomas
authors.initials: T
authors.lastname: Blystad
authors.forename: Sven-Börje
authors.initials: SB
authors.lastname: Ewers
authors.forename: Britta
authors.initials: B
authors.lastname: Löden
authors.forename: Michael
authors.initials: M
authors.lastname: Bergqvist
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000150:complications*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000150:complications / Q000401:mortality; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007964:Leukocytosis / Q000150:complications*; D008175:Lung Neoplasms / Q000097:blood* / Q000150:complications / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D012307:Risk Factors; D013548:Sweden; D013922:Thrombocytosis / Q000150:complications*